Hansa Biopharma AB Financial Flexibility Index
Hansa Biopharma AB financial flexibility index. Hansa Biopharma AB (HNSA) has a Financial Flexibility Index of -0.09x as of June 2025. Free cash flow of Skr-111.70 Million (operating CF Skr-111.70 Million minus capex Skr0.00) represents 0% of total liabilities (Skr1.28 Billion). See HNSA free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Hansa Biopharma AB (2008–2024)
Financial flexibility index of Hansa Biopharma AB from 2008 to 2024. Historical Financial Flexibility Index trend for Hansa Biopharma AB across 17 annual periods. Explore HNSA debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Hansa Biopharma AB Financial Flexibility Index by Year (2008–2024)
Hansa Biopharma AB financial flexibility index by year from 2008 to 2024. Year-by-year free cash flow to debt coverage for Hansa Biopharma AB. For the full cash flow conversion analysis, see Hansa Biopharma AB cash conversion from operations.
| Year | Flexibility Index | Free Cash Flow (SEK) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -0.49x | Skr-674.77 Million | Skr-674.88 Million | Skr1.39 Billion | ▲ +23.8% |
| 2023 | -0.64x | Skr-755.37 Million | Skr-755.65 Million | Skr1.19 Billion | ▼ -38.3% |
| 2022 | -0.46x | Skr-499.40 Million | Skr-502.73 Million | Skr1.08 Billion | ▲ +75.5% |
| 2021 | -1.88x | Skr-478.77 Million | Skr-481.17 Million | Skr255.24 Million | ▼ -24.4% |
| 2020 | -1.51x | Skr-289.98 Million | Skr-290.27 Million | Skr192.37 Million | ▲ +53.9% |
| 2019 | -3.27x | Skr-331.35 Million | Skr-334.77 Million | Skr101.42 Million | ▼ -37.3% |
| 2018 | -2.38x | Skr-202.07 Million | Skr-204.56 Million | Skr84.94 Million | ▲ +19.9% |
| 2017 | -2.97x | Skr-147.70 Million | Skr-150.10 Million | Skr49.75 Million | ▲ +14.4% |
| 2016 | -3.47x | Skr-93.58 Million | Skr-94.56 Million | Skr26.98 Million | ▲ +22.9% |
| 2015 | -4.50x | Skr-56.48 Million | Skr-57.80 Million | Skr12.56 Million | ▲ +9.6% |
| 2014 | -4.97x | Skr-22.42 Million | Skr-23.62 Million | Skr4.51 Million | ▼ -71.3% |
| 2013 | -2.90x | Skr-14.80 Million | Skr-14.87 Million | Skr5.10 Million | ▲ +58.6% |
| 2012 | -7.01x | Skr-17.93 Million | Skr-20.63 Million | Skr2.56 Million | ▼ -59.9% |
| 2011 | -4.39x | Skr-27.14 Million | Skr-27.14 Million | Skr6.19 Million | ▼ -36.6% |
| 2010 | -3.21x | Skr-18.09 Million | Skr-18.09 Million | Skr5.64 Million | ▼ -208.2% |
| 2009 | -1.04x | Skr-13.78 Million | Skr-13.79 Million | Skr13.23 Million | ▲ +63.0% |
| 2008 | -2.82x | Skr-11.64 Million | Skr-15.58 Million | Skr4.13 Million | — |